Rehmann Capital Advisory Group’s bluebird bio BLUE Stock Holding History

Rehmann Capital Advisory Group’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$10.2K	Buy	9 +2	+29%	+$3.05K	﹤0.01%	1045
2019 Q2	$11.8K	Hold	7	–	–	﹤0.01%	1294
2019 Q1	$14.6K	Hold	7	–	–	﹤0.01%	1215
2018 Q4	$9.22K	Buy	7 +2	+40%	+$3.07K	﹤0.01%	1079
2018 Q3	$10.2K	Sell	5 -1	-17%	-$2.07K	﹤0.01%	1354
2018 Q2	$11.8K	Buy	6 +1	+20%	+$2.28K	﹤0.01%	1284
2018 Q1	$12K	Buy	+5	New	+$12.7K	﹤0.01%	1233

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Rehmann Capital Advisory Group's BLUE Position: Q3 2019 in Review

Rehmann Capital Advisory Group increased its bluebird bio (BLUE) stake by 29% in Q3 2019, buying an estimated $3.05K and bringing the position to 9 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1045.

Rehmann Capital Advisory Group first reported a position in BLUE in Q1 2018 and has held it in 7 quarters since. The position peaked at $14.6K in Q1 2019. 241 funds tracked by Wall St. Rank hold BLUE as of Q3 2019.

Rehmann Capital Advisory Group held 9 shares of bluebird bio worth $10.2K as of Q3 2019.
Rehmann Capital Advisory Group bought 2 bluebird bio shares in Q3 2019, an estimated $3.05K.
bluebird bio made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1045 holding.
Rehmann Capital Advisory Group first reported a position in bluebird bio in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's bluebird bio position peaked at $14.6K in Q1 2019.
241 funds tracked by Wall St. Rank held bluebird bio as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.